Webcast - Oncopeptides withdraw Pepaxto in US, scale down organization and focus on R&D
October 22, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.
Investors, financial analysts, and media were invited to participate in a webcast including a Q&A the same day.
The event was hosted by CEO Marty J Duvall, CMO Klaas Bakker and CSO Jakob Lindberg. The presentation was held in English and was recorded.
More info, presentation and the webcast link